Rekah Pharmaceutical Industry Ltd.

TASE:REKA 株式レポート

時価総額：₪163.8m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Rekah Pharmaceutical Industry マネジメント

マネジメント 基準チェック /44

Rekah Pharmaceutical Industry'sの CEO はMordechai Elgrabliで、 Apr2015年に任命され、 の在任期間は 9.25年です。 の年間総報酬は₪ 1.01Mで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の15.32%を直接所有しており、その価値は₪ 27.75M 。経営陣と取締役会の平均在任期間はそれぞれ8.2年と9.3年です。

主要情報

Mordechai Elgrabli

最高経営責任者

₪1.0m

報酬総額

CEO給与比率100.0%
CEO在任期間9.4yrs
CEOの所有権15.3%
経営陣の平均在職期間8.4yrs
取締役会の平均在任期間9.4yrs

経営陣の近況

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Recent updates

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Jul 11
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Jul 05
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Sep 12
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Jul 19
Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

Apr 13
Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

May 12
We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Apr 09
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Mar 12
Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 19
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Jan 29
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

Jan 08
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Dec 18
How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Nov 30
Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

CEO報酬分析

Rekah Pharmaceutical Industry の収益と比較して、Mordechai Elgrabli の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

₪7m

Mar 31 2024n/an/a

-₪6m

Dec 31 2023₪1m₪1m

-₪7m

Sep 30 2023n/an/a

-₪8m

Jun 30 2023n/an/a

-₪3m

Mar 31 2023n/an/a

-₪2m

Dec 31 2022₪845k₪845k

-₪2m

Sep 30 2022n/an/a

₪4m

Jun 30 2022n/an/a

₪3m

Mar 31 2022n/an/a

₪5m

Dec 31 2021₪830k₪830k

₪7m

Sep 30 2021n/an/a

₪5m

Jun 30 2021n/an/a

₪9m

Mar 31 2021n/an/a

₪10m

Dec 31 2020₪828k₪828k

₪11m

Sep 30 2020n/an/a

₪7m

Jun 30 2020n/an/a

₪5m

Mar 31 2020n/an/a

₪4m

Dec 31 2019₪832k₪832k

₪3m

Sep 30 2019n/an/a

₪6m

Jun 30 2019n/an/a

₪5m

Mar 31 2019n/an/a

₪7m

Dec 31 2018₪801k₪801k

₪8m

Sep 30 2018n/an/a

₪246k

Jun 30 2018n/an/a

-₪8m

Mar 31 2018n/an/a

-₪11m

Dec 31 2017₪795k₪795k

-₪21m

報酬と市場: Mordechaiの 総報酬 ($USD 279.16K ) は、 IL市場 ($USD 535.50K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Mordechaiの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Mordechai Elgrabli (80 yo)

9.4yrs

在職期間

₪1,013,000

報酬

Mr. Mordechai Elgrabli has been the Chief Executive Officer of Rekah Pharmaceutical Industry Ltd since August 24, 1993 and its Director since August 24, 1993. Mr. Elgrabli is a Member of Presidium of Mofet...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Mordechai Elgrabli
CEO & Director9.4yrs₪1.01m15.32%
₪ 25.1m
Georgette Elgrabli
Director of Industrial Division & Directorno data₪1.62m15.32%
₪ 25.1m
Jacob Elgrably
Chief Executive Officer of Ophir Shalpharm7.3yrs₪920.00kデータなし
Nir Sella
Chief Executive Officer - Fresh of Life Pharma Ltd.2.9yrs₪907.00kデータなし
Meir Melumad
Director of Operationsno data₪684.00kデータなし
Yuval Elgrabli
Deputy CEO & Director of Business Development13.5yrsデータなしデータなし
Yaakov Elgrabli
Chief Executive Officer of Ophir & Shalpharm Ltdno data₪705.00k0.026%
₪ 43.1k

8.4yrs

平均在職期間

67.5yo

平均年齢

経験豊富な経営陣: REKAの経営陣は経験豊富で経験豊富です（平均在職期間は8.1年）。

取締役

名称ポジション在職期間報酬所有権
Mordechai Elgrabli
CEO & Director31.1yrs₪1.01m15.32%
₪ 25.1m
Georgette Elgrabli
Director of Industrial Division & Director31.1yrs₪1.62m15.32%
₪ 25.1m
Ishay Davidi
Director9.4yrsデータなしデータなし
Avraham Bigger
Chairman9.4yrs₪400.00kデータなし
Orly Zilberman
Independent External Director9.4yrsデータなしデータなし
Arnon Zo-Haaretz
Independent External Director7.8yrsデータなしデータなし
Ehud Nissan
Independent External Director7.8yrsデータなしデータなし
Amir Widmann
Directorless than a yearデータなしデータなし

9.4yrs

平均在職期間

67.5yo

平均年齢

経験豊富なボード: REKAの 取締役会 は 経験豊富 であると考えられます ( 9.2年の平均在任期間)。